Biologics and GLP-1 medicines keep absorbing capacity
Demand for injectable metabolic and diabetes therapies has pulled fill-finish and sterile injectable capacity towards a small number of manufacturers, with knock-on lead times for unrelated sterile products.
What it means for sourcing: Ask for confirmed fill-finish slots, not indicative lead times, and qualify a second sterile supplier before you need one.